SIGA Technologies, Inc. (SIGA)
NASDAQ: SIGA · IEX Real-Time Price · USD
8.63
-0.03 (-0.35%)
Apr 25, 2024, 10:50 AM EDT - Market open
Company Description
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States.
Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus.
The company was incorporated in 1995 and is headquartered in New York, New York.
SIGA Technologies, Inc.
| Country | United States |
| Founded | 1995 |
| IPO Date | Sep 9, 1997 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 45 |
| CEO | Dr. Diem Nguyen M.B.A., Ph.D. |
Contact Details
Address: 31 East 62nd Street New York, New York 10065 United States | |
| Phone | 212-672-9100 |
| Website | siga.com |
Stock Details
| Ticker Symbol | SIGA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001010086 |
| CUSIP Number | 826917106 |
| ISIN Number | US8269171067 |
| Employer ID | 13-3864870 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Daniel J. Luckshire | Executive Vice President, Chief Financial Officer and Secretary |
| Dr. Dennis E. Hruby | Executive Vice President and Chief Scientific Officer |
| Dr. Jay K. Varma M.D. | Executive Vice President, Chief Medical Officer and Director |
| Dr. Diem Nguyen M.B.A., Ph.D. | Chief Executive Officer and Director |
| Tove C. Bolken | Senior Vice President of Operations and Chief Supply Chain Officer |
| Herb Vloedman | Senior Vice President and Chief Information Officer |
| Lawrence R. Miller Esq., J.D. | General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 1, 2024 | 8-K | Current Report |
| Mar 12, 2024 | 10-K | Annual Report |
| Mar 12, 2024 | 8-K | Current Report |
| Feb 1, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jan 22, 2024 | 8-K | Current Report |
| Jan 2, 2024 | 8-K | Current Report |
| Nov 7, 2023 | 10-Q | Quarterly Report |
| Nov 7, 2023 | 8-K | Current Report |
| Sep 6, 2023 | 8-K | Current Report |
| Aug 8, 2023 | 10-Q | Quarterly Report |